Good News, Bad News and Comebacks. Some ASCO Results Too
This content is for members
Gilead Sciences (GILD)
An Approval & A Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio
This content is for members
Gilead Collaboration with Sangamo
Kite, a Gilead Company and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for Cancer Kite, a Gilead (GILD) …
In the Limelight
This content is for members
Celgene Acquires Juno Therapeutics at $9 Billion – $87 a Share. Why Array is Trading Around $15 in Premarket Today.
Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which, Celgene has agreed to acquire Juno. Celgene will pay $87 per …
The Year in Review Part 1
This content is for members
Gilead’s New Acquisition: An important Step Forward Towards Building a Superior Cancer Franchise
This content is for members
A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.
The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed …
The Week in Review
This content is for members
The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect
Important news has come from the FDA, which issued new guidelines to speed the introduction of treatments with human cells and tissues, including gene therapy. …
The Week in Review
This content is for members
The Week in Review
This content is for members
Gilead’s CAR T Drug Yescarta Is Approved for NHL Resisting Previous Treatments
As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration (FDA) has given the green light to a second CART …
New Breakthrough Immuno-Oncology Products
This content is for members
Gilead’s Acquisition Effect on Other CAR-T Developers’ Stocks
This content is for members